Drugs Competing For Active Tubular Secretion has 2 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Darunavir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide, Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Alafenamide. Patients taking Drugs Competing For Active Tubular Secretion should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 2
Moderate: 2

Moderate (2)

Drugs Competing For Active Tubular Secretion + Darunavir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide— Co-administration may increase concentrations of emtricitabine and tenofovir, increasing risk of adverse reactions.
Drugs Competing For Active Tubular Secretion + Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Alafenamide— Coadministration may increase concentrations of FTC and tenofovir by competing for renal tubular secretion.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.